SEC Filings

SAVARA INC filed this S-4/A on 20170313

Document Outline
Entire Document (9.6 MB)
Subdocument 1 - S-4/A - S-4/A
  Page 1 - As filed with the Securities and Exchange Commission on March 10, 2017
  Page 2 - The information in this proxy statement/prospectus/information statement is not complete and may be
  Page 3 - More information about Mast, Savara and the proposed transaction is contained in this proxy statemen
  Page 4 - MAST THERAPEUTICS, INC.
  Page 5 - vote of the holders of a majority of shares of Mast common stock having voting power outstanding on
  Page 6 - REFERENCES TO ADDITIONAL INFORMATION
  Page 7 - TABLE OF CONTENTS
  Page 8 - N/A
  Page 9 - N/A
  Page 10 - QUESTIONS AND ANSWERS ABOUT THE MERGER
  Page 11 - N/A
  Page 12 - N/A
  Page 13 - N/A
  Page 14 - N/A
  Page 15 - N/A
  Page 16 - N/A
  Page 17 - PROSPECTUS SUMMARY
  Page 18 - Opinion of the Mast Financial Advisor
  Page 19 - Treatment of Savara Options and Savara Restricted Shares
  Page 20 - Treatment of Savara Warrants
  Page 21 - Termination of the Merger Agreement
  Page 22 - Lock-Up Agreements
  Page 23 - Considerations with Respect to U.S. Federal Income Tax Consequences of the Merger
  Page 24 - Risk Factors
  Page 25 - Regulatory Approvals
  Page 26 - SELECTED HISTORICAL AND UNAUDITED PRO FORMA
  Page 27 - Condensed Consolidated Statements of Operations and Comprehensive Loss
  Page 28 - Selected Historical Consolidated Financial Data of Savara
  Page 29 - Selected Unaudited Pro Forma Condensed Combined Financial Data of Mast and Savara
  Page 30 - N/A
  Page 31 - Comparative Historical and Unaudited Pro Forma Per Share Data
  Page 32 - MARKET PRICE AND DIVIDEND INFORMATION
  Page 33 - RISK FACTORS
  Page 34 - If the conditions to the merger are not met, the merger may not occur.
  Page 35 - The market price of Mast common stock following the merger may decline as a result of the merger.
  Page 36 - Because the lack of a public market for Savara shares makes it difficult to evaluate the fairness of
  Page 37 - There is substantial doubt as to Mast s ability to continue as a going concern.
  Page 38 - Mast s product candidates are at intermediary to early stages of development, the success of Mast s
  Page 39 - N/A
  Page 40 - Mast will need to obtain additional funding to pursue its current business strategy and continue as
  Page 41 - If Mast is unable to consummate the merger with Savara or raise sufficient additional capital as nee
  Page 42 - Mast s ability to raise capital may be limited by applicable laws and regulations.
  Page 43 - Mast has significant goodwill and IPR D and impairment of goodwill and IPR D may have a significant
  Page 44 - Loss of personnel, through reductions in force or otherwise, could adversely impact Mast s ability t
  Page 45 - Mast expends substantial resources to comply with laws and regulations relating to public companies,
  Page 46 - Mast s employees, independent contractors and consultants, principal investigators, CROs, CMOs and o
  Page 47 - All ongoing and currently planned clinical studies of Mast s lead product candidate, AIR001, are inv
  Page 48 - N/A
  Page 49 - Clinical studies are very expensive, difficult to design and implement, often take many years to com
  Page 50 - N/A
  Page 51 - Mast does not have, and does not have plans to establish, any manufacturing facilities and are depen
  Page 52 - N/A
  Page 53 - Mast relies significantly on third parties to conduct its nonclinical testing and clinical studies a
  Page 54 - Mast may not achieve its projected development goals in the time frames Mast announces.
  Page 55 - Even if Mast receives regulatory approval for a product candidate, Mast may face development and reg
  Page 56 - Even if Mast receives regulatory approval to market one or more of its product candidates in the U.S
  Page 57 - N/A
  Page 58 - Mast s success depends in large part on its ability to prevent competitors from duplicating or devel
  Page 59 - Obtaining and maintaining Mast s patent protection depends on compliance with various procedural, do
  Page 60 - N/A
  Page 61 - Risks Related to Mast s Industry
  Page 62 - Mast faces potential product liability exposure and, if successful claims are brought against it, Ma
  Page 63 - Risks Related to Mast s Common Stock
  Page 64 - If Mast s common stock were delisted and determined to be a penny stock, a broker-dealer may find it
  Page 65 - Mast s stock price could decline significantly based on progress with and results of its clinical st
  Page 66 - Sales of substantial amounts of Mast s common stock or the perception that such sales may occur coul
  Page 67 - If Mast were to issue shares of its common stock or preferred stock that are available for issuance,
  Page 68 - N/A
  Page 69 - Risks Related to Savara s Business Strategy and Operations
  Page 70 - If Savara fails to attract and retain senior management and key scientific personnel, it may be unab
  Page 71 - Savara does not have, and does not have plans to establish manufacturing facilities. Savara complete
  Page 72 - N/A
  Page 73 - Savara relies significantly on third parties to conduct its nonclinical testing and clinical studies
  Page 74 - Savara is the process of integrating the systems, people and contracts from the recent acquisition o
  Page 75 - Savara may not achieve its projected development goals in the time frames Savara has announced.
  Page 76 - Savara s employees, independent contractors and consultants, principal investigators, CROs, CMOs and
  Page 77 - Risks Related to Drug Development and Commercialization
  Page 78 - Delays in commencement and completion of clinical studies are common and have many causes. Delays in
  Page 79 - N/A
  Page 80 - Clinical studies are very expensive, difficult to design and implement, often take many years to com
  Page 81 - N/A
  Page 82 - Even if Savara receives regulatory approval for a product candidate, Savara may face regulatory diff
  Page 83 - If any of Savara s product candidates for which Savara receive regulatory approval fails to achieve
  Page 84 - Savara must comply with the U.S. Foreign Corrupt Practices Act and similar foreign anti-corruption l
  Page 85 - N/A
  Page 86 - Savara s success depends on its ability to prevent competitors from duplicating or developing and co
  Page 87 - Obtaining and maintaining patent protection depends on compliance with various procedural, document
  Page 88 - Risks Related to Savara s Industry
  Page 89 - Savara is subject to uncertainty relating to healthcare reform measures and reimbursement policies t
  Page 90 - Savara faces potential product liability exposure and, if successful claims are brought against it,
  Page 91 - Risks Related to the Combined Organization
  Page 92 - The combined organization will incur costs and demands upon management as a result of complying with
  Page 93 - The combined company does not expect to pay any cash dividends in the foreseeable future.
  Page 94 - CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
  Page 95 - THE SPECIAL MEETING OF MAST STOCKHOLDERS
  Page 96 - Record Date and Voting Power
  Page 97 - Required Vote
  Page 98 - Solicitation of Proxies
  Page 99 - THE MERGER
  Page 100 - N/A
  Page 101 - N/A
  Page 102 - N/A
  Page 103 - N/A
  Page 104 - N/A
  Page 105 - N/A
  Page 106 - N/A
  Page 107 - N/A
  Page 108 - N/A
  Page 109 - Mast Reasons for the Merger
  Page 110 - N/A
  Page 111 - N/A
  Page 112 - Savara Reasons for the Merger
  Page 113 - Opinion of Roth Capital Partners as Mast s Financial Advisor
  Page 114 - The summary of Roth s opinion in this proxy statement is qualified in its entirety by reference to t
  Page 115 - N/A
  Page 116 - Consideration to be Paid in the Merger
  Page 117 - Estimated Mast Stand-Alone Valuation
  Page 118 - Discounted Cash Flow Analysis
  Page 119 - Mast Therapeutics, Inc.
  Page 120 - Private Valuation Step-up Analysis
  Page 121 - Public Comparable Analysis Respiratory
  Page 122 - Respiratory Licensing Comparables
  Page 123 - Discounted Cash Flow Analysis
  Page 124 - Savara Inc.
  Page 125 - Savara Inc.
  Page 126 - Information Regarding Financial Projections Used for Fairness Opinion Analysis
  Page 127 - Potential Benefits upon Change in Control of Mast
  Page 128 - Cash and Restricted Stock Unit Awards
  Page 129 - Restricted Stock Units Awards
  Page 130 - Acceleration of Director Equity Awards
  Page 131 - Interests of Certain Savara Directors, Executive Officers and Affiliates in the Merger
  Page 132 - Stock Options and Warrants.
  Page 133 - Management Following the Merger
  Page 134 - Stock Options, Restricted Stock and Warrants
  Page 135 - Merger Consideration
  Page 136 - Effective Time of the Merger
  Page 137 - N/A
  Page 138 - STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL I
  Page 139 - Information Reporting and Backup Withholding
  Page 140 - THE PRECEDING DISCUSSION DOES NOT PURPORT TO BE A COMPLETE ANALYSIS OR DISCUSSION OF ALL OF THE MERG
  Page 141 - N/A
  Page 142 - Weinberger
  Page 143 - Weinberger
  Page 144 - THE MERGER AGREEMENT
  Page 145 - Exchange Ratio
  Page 146 - Determination of Net Cash
  Page 147 - minus
  Page 148 - Treatment of Savara Options and Savara Restricted Shares
  Page 149 - Amendments to the Amended and Restated Certificate of Incorporation of Mast
  Page 150 - N/A
  Page 151 - N/A
  Page 152 - Representations and Warranties
  Page 153 - No Solicitation
  Page 154 - N/A
  Page 155 - Meetings of Stockholders
  Page 156 - Covenants; Conduct of Business Pending the Merger
  Page 157 - N/A
  Page 158 - N/A
  Page 159 - Regulatory Approvals
  Page 160 - Financing
  Page 161 - Other Agreements
  Page 162 - N/A
  Page 163 - Termination of the Merger Agreement
  Page 164 - N/A
  Page 165 - Termination Fee
  Page 166 - Fee payable by Savara
  Page 167 - AGREEMENTS RELATED TO THE MERGER
  Page 168 - N/A
  Page 169 - MATTERS BEING SUBMITTED TO A VOTE OF MAST STOCKHOLDERS
  Page 170 - Mast Proposal No. 2: Approval of the Amendment and Restatement of the Amended and Restated Certifica
  Page 171 - Potential Increased Investor Interest
  Page 172 - Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates
  Page 173 - Potential Anti-Takeover Effect
  Page 174 - INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCO
  Page 175 - Information Reporting and Backup Withholding
  Page 176 - Mast Proposal No. 4: Advisory Non-Binding Vote on Merger-Related Executive Compensation Arrangements
  Page 177 - Mast Proposal No. 5: Approval of Possible Adjournment of the Mast Special Meeting
  Page 178 - MAST BUSINESS
  Page 179 - Rationale for Development of AIR001 in HFpEF
  Page 180 - Journal of Clinical Investigation
  Page 181 - Phase 2 INABLE-TRAINING Study
  Page 182 - Future Development in HFpEF
  Page 183 - Intellectual Property
  Page 184 - Competition
  Page 185 - N/A
  Page 186 - N/A
  Page 187 - N/A
  Page 188 - Expedited Review Programs
  Page 189 - N/A
  Page 190 - Other Healthcare Laws and Compliance Requirements
  Page 191 - Government Regulation Outside the U.S.
  Page 192 - SAVARA BUSINESS
  Page 193 - Savara s product candidate pipeline
  Page 194 - Change from baseline in FEV1 (left) and Time to use of other antibiotic for respiratory infection (r
  Page 195 - Strategy
  Page 196 - Current MRSA treatment options in CF
  Page 197 - AeroVanc Product Description
  Page 198 - Completed Clinical Studies
  Page 199 - Phase 2
  Page 200 - Vancomycin sputum concentrations after administration of AeroVanc at various time points
  Page 201 - Change from baseline in FEV1
  Page 202 - Change in MRSA density in sputum
  Page 203 - Time to use of other antibiotics for respiratory infection
  Page 204 - Current treatment options of PAP
  Page 205 - Molgradex Product Description
  Page 206 - Completed Clinical Studies
  Page 207 - Mean WBC Over Time and After Multiple Ascending Doses
  Page 208 - Molgradex Pharmacology Studies
  Page 209 - GM-CSF receptor function by Molgradex or control recombinant human GM-CSF
  Page 210 - Manufacturing and Supply
  Page 211 - Molgradex Manufacturing
  Page 212 - PARI Pharma GmbH
  Page 213 - Government Regulation
  Page 214 - in vitro
  Page 215 - NDA Submission and Review by the FDA
  Page 216 - N/A
  Page 217 - Orphan Drug Status
  Page 218 - Post-Approval Requirements
  Page 219 - Government Regulation of Combination Products
  Page 220 - N/A
  Page 221 - N/A
  Page 222 - Coverage and Reimbursement
  Page 223 - Foreign Regulation
  Page 224 - Trade Secrets
  Page 225 - in vitro
  Page 226 - Employees
  Page 227 - MAST MANAGEMENT S DISCUSSION AND ANALYSIS OF
  Page 228 - Critical Accounting Policies and Significant Judgments and Estimates
  Page 229 - Business Combinations
  Page 230 - Goodwill for Impairment
  Page 231 - Results of Operations Overview
  Page 232 - Selling, General and Administrative Expenses.
  Page 233 - Other (Expense)/Income, Net.
  Page 234 - Selling, General and Administrative Expenses
  Page 235 - Operating Expenses
  Page 236 - Transaction-Related Expenses.
  Page 237 - Liquidity and Capital Resources
  Page 238 - N/A
  Page 239 - N/A
  Page 240 - Operating activities
  Page 241 - Recent Accounting Pronouncements
  Page 242 - QUANTITATIVE AND QUALITATIVE DISCLOSURES
  Page 243 - SAVARA MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
  Page 244 - Recent Events
  Page 245 - General and Administrative Expenses
  Page 246 - Fair Value of Common Stock
  Page 247 - Results of Operations Comparison of Years Ended December 31, 2016 and 2015
  Page 248 - Liquidity and Capital Resources
  Page 249 - Cash Flows
  Page 250 - Contractual Obligations and Other Commitments
  Page 251 - License and Royalty Agreements
  Page 252 - Off-Balance Sheet Arrangements
  Page 253 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT SAVARA MARKET RISK
  Page 254 - MANAGEMENT FOLLOWING THE MERGER
  Page 255 - David Lowrance
  Page 256 - Joseph S. McCracken
  Page 257 - Composition of the Board of Directors
  Page 258 - Compensation Committee
  Page 259 - Nominating and Governance Committee
  Page 260 - N/A
  Page 261 - 2016 Savara Director Compensation
  Page 262 - Executive Compensation
  Page 263 - Non-Equity Incentive Plan
  Page 264 - Employment and Severance Agreements
  Page 265 - Employment Benefits Plans
  Page 266 - Mast s 2015 Omnibus Incentive Plan
  Page 267 - Eligibility; Awards to Certain Individuals and Groups.
  Page 268 - Stock Options.
  Page 269 - Restricted Stock Awards.
  Page 270 - N/A
  Page 271 - Adjustments to Awards Subject to Performance Criteria.
  Page 272 - Nontransferability of Awards.
  Page 273 - Termination of Employment.
  Page 274 - CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF SAVARA
  Page 275 - Series B Preferred Stock Warrants
  Page 276 - UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
  Page 277 - N/A
  Page 278 - Unaudited Pro Forma Condensed Combined Balance Sheet
  Page 279 - Unaudited Pro Forma Condensed Combined Statement of Operations
  Page 280 - NOTES TO THE UNAUDITED PRO FORMA CONDENSED
  Page 281 - 3. Pro Forma Adjustments
  Page 282 - N/A
  Page 283 - 4. Serendex s Historical Financial Statements
  Page 284 - Translation of Serendex s Historical Financial Statements to US Dollars
  Page 285 - DESCRIPTION OF MAST CAPITAL STOCK
  Page 286 - Anti-Takeover Effects of Provisions of Mast s Charter Documents and Delaware Law
  Page 287 - No Cumulative Voting
  Page 288 - N/A
  Page 289 - COMPARISON OF RIGHTS OF HOLDERS OF MAST STOCK AND SAVARA STOCK
  Page 290 - N/A
  Page 291 - N/A
  Page 292 - N/A
  Page 293 - N/A
  Page 294 - N/A
  Page 295 - PRINCIPAL STOCKHOLDERS OF MAST
  Page 296 - N/A
  Page 297 - N/A
  Page 298 - PRINCIPAL STOCKHOLDERS OF SAVARA
  Page 299 - N/A
  Page 300 - LEGAL MATTERS
  Page 301 - TRADEMARK NOTICE
  Page 302 - INDEX TO FINANCIAL STATEMENTS
  Page 303 - Report of Independent Registered Public Accounting Firm
  Page 304 - Report of Independent Registered Public Accounting Firm
  Page 305 - Report of Independent Registered Public Accounting Firm
  Page 306 - Mast Therapeutics, Inc. and Subsidiaries
  Page 307 - Mast Therapeutics, Inc. and Subsidiaries
  Page 308 - Mast Therapeutics, Inc. and Subsidiaries
  Page 309 - Mast Therapeutics, Inc. and Subsidiaries
  Page 310 - Mast Therapeutics, Inc. and Subsidiaries
  Page 311 - Liquidity as of December 31, 2015
  Page 312 - Business Combinations
  Page 313 - Property and Equipment
  Page 314 - Concentration of Credit Risk and Significant Sources of Supply
  Page 315 - Research and Development Expense
  Page 316 - Comprehensive Income/(Loss)
  Page 317 - Leases (ASC 842)
  Page 318 - Acquired In-Process Research and Development
  Page 319 - Deferred Income Tax Liability
  Page 320 - N/A
  Page 321 - N/A
  Page 322 - Hercules Loan and Security Agreement
  Page 323 - Summary of Carrying Value
  Page 324 - Underwritten Public Offering of Common Stock and Warrants
  Page 325 - Warrant Exercises
  Page 326 - 2015 Omnibus Incentive Plan
  Page 327 - Summary of 2016 Stock Option Activity
  Page 328 - Compensation Stock Compensation
  Page 329 - N/A
  Page 330 - N/A
  Page 331 - N/A
  Page 332 - Quarterly statements of operations data
  Page 333 - Fifth Amendment to Loan Agreement and Third Amendment to Warrant Agreement with Hercules
  Page 334 - Anticipated Severance Expense
  Page 335 - Report of Independent Auditors
  Page 336 - Savara Inc. and Subsidiary
  Page 337 - Savara Inc. and Subsidiary
  Page 338 - Savara Inc. and Subsidiary
  Page 339 - Savara Inc. and Subsidiary
  Page 340 - Savara Inc. and Subsidiary
  Page 341 - Principles of Consolidation
  Page 342 - Concentration of Credit Risk
  Page 343 - Property and Equipment
  Page 344 - Segment Reporting
  Page 345 - Stock-Based Compensation
  Page 346 - N/A
  Page 347 - 3. Property and Equipment, Net
  Page 348 - Voluntary Conversion
  Page 349 - Accounting for 2014 Notes
  Page 350 - Voluntary Conversion
  Page 351 - IPO Conversion
  Page 352 - 5. Litigation
  Page 353 - 7. Acquisition of Serendex Pharmaceuticals
  Page 354 - Pro Forma Financial Information
  Page 355 - 9. Fair Value Measurements
  Page 356 - N/A
  Page 357 - 10. Redeemable Convertible Preferred Stock
  Page 358 - Liquidation
  Page 359 - Dividend and Voting Rights
  Page 360 - Stock Options
  Page 361 - Restricted Stock
  Page 362 - 13. Income Taxes
  Page 363 - N/A
  Page 364 - 14. Net Loss per Share
  Page 365 - Modification of the 2016 Notes
  Page 366 - INDEPENDENT AUDITOR S REPORT
  Page 367 - Consolidated Income Statement
  Page 368 - Consolidated Balance Sheet
  Page 369 - Consolidated Changes in equity
  Page 370 - Consolidated Cash Flow Statement
  Page 371 - Notes
  Page 372 - 3. SEGMENT DATA
  Page 373 - Assumptions for warrants granted in 2015
  Page 374 - 6. FEE TO STATUTORY AUDITORS
  Page 375 - 10. ALLOCATION OF LOSS
  Page 376 - 13. DEPOSITS
  Page 377 - 16. LOANS FROM SHAREHOLDERS
  Page 378 - 21. STATEMENT OF CASH FLOWS ADJUSTMENTS
  Page 379 - Commercial risks
  Page 380 - Capital resources
  Page 381 - 25. BOARD OF DIRECTORS AND EXECUTIVE MANAGEMENT
  Page 382 - EXECUTIVE MANAGEMENT
  Page 383 - Basis of consolidation
  Page 384 - Cost of goods sold
  Page 385 - BALANCE SHEET ITEMS
  Page 386 - Write-down of assets
  Page 387 - Other receivables, prepayments and accrued expenses
  Page 388 - Unaudited Consolidated Income Statement
  Page 389 - Unaudited Consolidated Balance Sheet
  Page 390 - Unaudited Consolidated Changes in equity
  Page 391 - Unaudited Consolidated Cash Flow Statement
  Page 392 - Unaudited Notes
  Page 393 - Development costs
  Page 394 - 4. OTHER EXPENSES AND COSTS BY FUNCTION
  Page 395 - 7. TAX RECEIVABLES AND DEFERRED TAX
  Page 396 - 10. STATEMENT OF CASH FLOWS ADJUSTMENTS
  Page 397 - New standards and interpretations
  Page 398 - Translation of foreign currency
  Page 399 - Staff expenses
  Page 400 - Tangible assets
  Page 401 - Deferred tax
  Page 402 - Cash flow from capitalised activities
  Page 403 - Annex A
  Page 404 - N/A
  Page 405 - N/A
  Page 406 - Exhibits
  Page 407 - AGREEMENT AND PLAN OF MERGER AND REORGANIZATION
  Page 408 - Parent
  Page 409 - 1.4 Certificate of Incorporation; Bylaws; Reverse Split; Parent Name Change.
  Page 410 - (d)
  Page 411 - 1.7 Dissenting Shares
  Page 412 - (c)
  Page 413 - 1.10 Calculation of Net Cash.
  Page 414 - 1.11 No Further Rights
  Page 415 - (c)
  Page 416 - 2.3 Authority; Non-Contravention; Approvals
  Page 417 - SEC
  Page 418 - Liability
  Page 419 - (e)
  Page 420 - 2.8 Intellectual Property
  Page 421 - (f)
  Page 422 - (c)
  Page 423 - (g)
  Page 424 - ERISA
  Page 425 - (d)
  Page 426 - (h)
  Page 427 - (b)
  Page 428 - 2.16 Company Contracts.
  Page 429 - (xi)
  Page 430 - (b)
  Page 431 - (b)
  Page 432 - 3.3 Authority; Non-Contravention; Approvals.
  Page 433 - 3.4 Anti-Takeover Statutes Not Applicable
  Page 434 - (f)
  Page 435 - (c)
  Page 436 - (b)
  Page 437 - (c)
  Page 438 - (b)
  Page 439 - (d)
  Page 440 - (h)
  Page 441 - (i)
  Page 442 - (xiii)
  Page 443 - 3.17 Disclosure
  Page 444 - (b)
  Page 445 - (k)
  Page 446 - (f)
  Page 447 - (o)
  Page 448 - (c)
  Page 449 - (b)
  Page 450 - Parent Stockholder Approval Matters
  Page 451 - provided
  Page 452 - Confidentiality Agreement
  Page 453 - 5.7 Notification of Certain Matters
  Page 454 - 5.11 Board of Directors and Officers of Parent
  Page 455 - (b)
  Page 456 - Acceptable Parent Confidentiality Agreement
  Page 457 - 5.17 Company Options; Restricted Shares
  Page 458 - (d)
  Page 459 - 5.22 Company and Parent Disclosure Schedules
  Page 460 - (b)
  Page 461 - ARTICLE 6
  Page 462 - (c)
  Page 463 - (d)
  Page 464 - (f)
  Page 465 - (ii)
  Page 466 - (f)
  Page 467 - (b)
  Page 468 - 8.5 Entire Agreement.
  Page 469 - (c)
  Page 470 - knowledge of Parent
  Page 471 - IN WITNESS WHEREOF
  Page 472 - EXHIBIT A
  Page 473 - Company Disclosure Schedule
  Page 474 - Consent
  Page 475 - provided
  Page 476 - FDA
  Page 477 - Legal Proceeding
  Page 478 - Parent Capital Stock
  Page 479 - Parent Unaudited Interim Balance Sheet
  Page 480 - Proxy Statement/Prospectus/ Information Statement
  Page 481 - provided
  Page 482 - N/A
  Page 483 - N/A
  Page 484 - Exhibit A Lock-Up Agreement Signatories
  Page 485 - Annex B
  Page 486 - N/A
  Page 487 - N/A
  Page 488 - Annex C
  Page 489 - N/A
  Page 490 - N/A
  Page 491 - N/A
  Page 492 - Annex D
  Page 493 - ARTICLE V
  Page 494 - PART II
  Page 495 - (a) Exhibit Index
  Page 496 - N/A
  Page 497 - SIGNATURES
  Page 498 - EXHIBIT INDEX
  Page 499 - N/A
  Page 500 - N/A
  Page 501 - N/A
  Page 502 - N/A
  Page 503 - N/A
  Page 504 - N/A
  Page 505 - Incorporated by Reference
Subdocument 2 - EX-5.1 - EX-5.1
  Page 1 - Company
Subdocument 3 - EX-8.1 - EX-8.1
  Page 1 - Exhibit 8.1
  Page 2 - N/A
Subdocument 4 - EX-8.2 - EX-8.2
  Page 1 - Exhibit 8.2
  Page 2 - N/A
Subdocument 5 - EX-10.56 - EX-10.56
  Page 1 - Exhibit 10.56
  Page 2 - Target Bonus
  Page 3 - Termination without Cause or Resignation for Good Reason within the Change of Control Period
  Page 4 - Disability; Death
  Page 5 - Limitation on Payments
  Page 6 - Definition of Terms
  Page 7 - Change of Control Period
  Page 8 - Assignment
  Page 9 - Governing Law
  Page 10 - [SIGNATURE PAGE TO EXECUTIVE EMPLOYMENT AGREEMENT]
  Page 11 - EXHIBIT A
  Page 12 - Release of Claims
  Page 13 - to be modified in accordance with the ADEA, the Older Workers Benefit Protection Act, and other appl
  Page 14 - No Pending or Future Lawsuits
  Page 15 - No Admission of Liability
  Page 16 - Authority
  Page 17 - solely
  Page 18 - N/A
Subdocument 6 - EX-10.57 - EX-10.57
  Page 1 - Exhibit 10.57
  Page 2 - Target Bonus
  Page 3 - Termination without Cause or Resignation for Good Reason within the Change of Control Period
  Page 4 - Disability; Death
  Page 5 - Limitation on Payments
  Page 6 - Definition of Terms
  Page 7 - Change of Control Period
  Page 8 - Assignment
  Page 9 - Governing Law
  Page 10 - [SIGNATURE PAGE TO EXECUTIVE EMPLOYMENT AGREEMENT]
  Page 11 - EXHIBIT A
  Page 12 - Release of Claims
  Page 13 - to be modified in accordance with the ADEA, the Older Workers Benefit Protection Act, and other appl
  Page 14 - No Pending or Future Lawsuits
  Page 15 - No Admission of Liability
  Page 16 - No Representations
  Page 17 - solely
  Page 18 - N/A
Subdocument 7 - EX-10.58 - EX-10.58
  Page 1 - Exhibit 10.58
  Page 2 - Target Bonus
  Page 3 - Continued Employee Benefits
  Page 4 - COBRA Reimbursements
  Page 5 - Section 409A
  Page 6 - Limitation on Payments
  Page 7 - Change of Control Period
  Page 8 - Section 409A
  Page 9 - Integration
  Page 10 - [SIGNATURE PAGE TO EXECUTIVE EMPLOYMENT AGREEMENT]
  Page 11 - EXHIBIT A
  Page 12 - Release of Claims
  Page 13 - to be modified in accordance with the ADEA, the Older Workers Benefit Protection Act, and other appl
  Page 14 - No Pending or Future Lawsuits
  Page 15 - No Admission of Liability
  Page 16 - Authority
  Page 17 - solely
  Page 18 - N/A
Subdocument 8 - EX-10.59 - EX-10.59
  Page 1 - Exhibit 10.59
  Page 2 - Agreement Quarters
  Page 3 - Purchase Price
  Page 4 - however
  Page 5 - Standard Forms
  Page 6 - Rejected API
  Page 7 - Disclaimer of Warranties.
  Page 8 - Termination
  Page 9 - Force Majeure
  Page 10 - Section
  Page 11 - provided, however
  Page 12 - Entire Agreement
  Page 13 - N/A
  Page 14 - EXHIBIT A PRICES AND ADJUSTMENTS
  Page 15 - EXHIBIT B SPECIFICATIONS
  Page 16 - EXHIBIT B SPECIFICATIONS
  Page 17 - Storage condition
Subdocument 9 - EX-10.60 - EX-10.60
  Page 1 - Exhibit 10.60
  Page 2 - Confidential Information
  Page 3 - Product(s)
  Page 4 - N/A
  Page 5 - N/A
  Page 6 - N/A
  Page 7 - N/A
  Page 8 - N/A
  Page 9 - N/A
  Page 10 - N/A
  Page 11 - N/A
  Page 12 - N/A
  Page 13 - N/A
  Page 14 - N/A
  Page 15 - [THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK;
  Page 16 - Execution
  Page 17 - Prices valid at the date of Signature of Supply Agreement
  Page 18 - SUPPLY AGREEMENT
  Page 19 - IN WITNESS WHEREOF
Subdocument 10 - EX-10.61 - EX-10.61
  Page 1 - Exhibit 10.61
  Page 2 - CONTENTS
  Page 3 - SUPPLY AND LICENSE AGREEMENT
  Page 4 - Active Pharmaceutical Ingredient
  Page 5 - Field
  Page 6 - Process Change Request
  Page 7 - N/A
  Page 8 - N/A
  Page 9 - N/A
  Page 10 - N/A
  Page 11 - N/A
  Page 12 - N/A
  Page 13 - N/A
  Page 14 - N/A
  Page 15 - N/A
  Page 16 - APPENDICES
  Page 17 - Appendix 1
  Page 18 - Appendix 2
  Page 19 - Appendix 3
  Page 20 - Appendix 4
  Page 21 - Appendix 5
  Page 22 - Appendix 6
  Page 23 - Appendix 7
  Page 24 - Appendix 9
  Page 25 - Appendix 11
  Page 26 - Appendix 12
  Page 27 - N/A
  Page 28 - Appendices
  Page 29 - N/A
  Page 30 - N/A
  Page 31 - N/A
  Page 32 - N/A
  Page 33 - N/A
  Page 34 - N/A
  Page 35 - N/A
  Page 36 - N/A
  Page 37 - N/A
  Page 38 - N/A
  Page 39 - N/A
  Page 40 - N/A
  Page 41 - Appendix 1 : Introduction and Scope
  Page 42 - Appendix2: Transfer Plan
  Page 43 - N/A
  Page 44 - Appendix3: List of Technology Assets
  Page 45 - Appendix4: Technical Information
  Page 46 - 19.1.1.1 Synthetic route
  Page 47 - Appendix 5: Requirements for training of CMO personnel
  Page 48 - Appendix 6: API Specifications
Subdocument 11 - EX-23.1 - EX-23.1
  Page 1 - Exhibit 23.1
Subdocument 12 - EX-23.2 - EX-23.2
  Page 1 - Exhibit 23.2
Subdocument 13 - EX-23.3 - EX-23.3
  Page 1 - Exhibit 23.3
Subdocument 14 - EX-23.4 - EX-23.4
  Page 1 - Exhibit 23.4
Subdocument 15 - EX-99.1 - EX-99.1
  Page 1 - Exhibit 99.1
  Page 2 - N/A
Subdocument 16 - EX-99.5 - EX-99.5
  Page 1 - Exhibit 99.5
Subdocument 17 - EX-99.6 - EX-99.6
  Page 1 - Exhibit 99.6
Subdocument 18 - EX-99.7 - EX-99.7
  Page 1 - Exhibit 99.7
Subdocument 19 - EX-99.8 - EX-99.8
  Page 1 - Exhibit 99.8
Subdocument 20 - EX-99.9 - EX-99.9
  Page 1 - Exhibit 99.9